• No results found

University of Groningen Kinome directed target discovery and validation in unique ovarian clear cell carcinoma models Caumanns, Joost

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Kinome directed target discovery and validation in unique ovarian clear cell carcinoma models Caumanns, Joost"

Copied!
7
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Kinome directed target discovery and validation in unique ovarian clear cell carcinoma models

Caumanns, Joost

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Caumanns, J. (2019). Kinome directed target discovery and validation in unique ovarian clear cell carcinoma models. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

526956-L-sub01-bw-Caumanns 526956-L-sub01-bw-Caumanns 526956-L-sub01-bw-Caumanns 526956-L-sub01-bw-Caumanns Processed on: 7-12-2018 Processed on: 7-12-2018 Processed on: 7-12-2018

Processed on: 7-12-2018 PDF page: 1PDF page: 1PDF page: 1PDF page: 1

Kinome directed target

discovery and validation in

unique ovarian clear cell

carcinoma models

(3)

526956-L-sub01-bw-Caumanns 526956-L-sub01-bw-Caumanns 526956-L-sub01-bw-Caumanns 526956-L-sub01-bw-Caumanns Processed on: 7-12-2018 Processed on: 7-12-2018 Processed on: 7-12-2018

Processed on: 7-12-2018 PDF page: 2PDF page: 2PDF page: 2PDF page: 2

The research in this thesis was supported by a grant from the Dutch Cancer Society (KWF, RUG2012-5477)

Printing of this thesis was supported by: - UMCG Graduate School of Medical Sciences - Stichting Werkgroep Interne Oncologie - University of Groningen

ISBN: 978-94-034-1303-7

Cover: A.M. Heijink, J.J. Caumanns

lay-out design: A.M. Heijink, J.J. Caumanns, & N. van den Tempel Printing: Ipskamp Printing

Copyright © 2019, J.J. Caumanns

All rights reserved. No part of this thesis may be reproduced, stored or transmitted in any form or by any means without permission of the author.

(4)

526956-L-sub01-bw-Caumanns 526956-L-sub01-bw-Caumanns 526956-L-sub01-bw-Caumanns 526956-L-sub01-bw-Caumanns Processed on: 7-12-2018 Processed on: 7-12-2018 Processed on: 7-12-2018

Processed on: 7-12-2018 PDF page: 3PDF page: 3PDF page: 3PDF page: 3

Kinome directed target discovery and

validation in unique ovarian clear cell

carcinoma models

Proefschrift

ter verkrijging van de graad van doctor aan de

Rijksuniversiteit Groningen

op gezag van de

UHFWRUPDJQL¿FXVSURIGUE. Sterken

en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op

16 januari 2019 om 16:15 uur

door

Joseph Johannes Caumanns

geboren op 16 November 1990

(5)

526956-L-sub01-bw-Caumanns 526956-L-sub01-bw-Caumanns 526956-L-sub01-bw-Caumanns 526956-L-sub01-bw-Caumanns Processed on: 7-12-2018 Processed on: 7-12-2018 Processed on: 7-12-2018

Processed on: 7-12-2018 PDF page: 4PDF page: 4PDF page: 4PDF page: 4

Promotores

Prof. dr. S. de Jong Prof. dr. A.G.J van der Zee

Co-promotor

dr. G.B.A. Wisman

Beoordelingscommissie

Prof. dr. F.C. Amant Prof. dr. J.J. Schuringa Prof. dr. F.A.E Kruyt

(6)

526956-L-sub01-bw-Caumanns 526956-L-sub01-bw-Caumanns 526956-L-sub01-bw-Caumanns 526956-L-sub01-bw-Caumanns Processed on: 7-12-2018 Processed on: 7-12-2018 Processed on: 7-12-2018

Processed on: 7-12-2018 PDF page: 5PDF page: 5PDF page: 5PDF page: 5

TABLE OF CONTENTS

Chapter 1 Introduction and thesis outline 7

Chapter 2 ARID1A mutant ovarian clear cell carcinoma: A clear target

for synthetic lethal strategies Biochim Biophys Acta, 2018

17

Chapter 3 ARID1A mutation sensitizes most ovarian clear cell

carcinomas to BET inhibitors Oncogene, 2018

35

Chapter 4 ,QWHJUDWLYHNLQRPHSUR¿OLQJLGHQWL¿HVP725&LQKLELWLRQ as treatment strategy in ovarian clear cell carcinoma Clinical Cancer Research, 2018

61 Chapter 5 /RZGRVHWULSOHGUXJFRPELQDWLRQWDUJHWLQJWKH3,. $.7P725SDWKZD\DQGWKH0$3.SDWKZD\LVDKLJKO\ HႇHFWLYHDSSURDFKLQRYDULDQFOHDUFHOOFDUFLQRPD Submitted 97

Chapter 6 Establishment and characterization of ovarian clear cell carcinoma patient-derived xenograft models

Manuscript in preparation

117

Chapter 7 Summary and discussion 137

Appendix Nederlandse samenvatting List of abbreviations Biography

List of publications Dankwoord

(7)

526956-L-sub01-bw-Caumanns 526956-L-sub01-bw-Caumanns 526956-L-sub01-bw-Caumanns 526956-L-sub01-bw-Caumanns Processed on: 7-12-2018 Processed on: 7-12-2018 Processed on: 7-12-2018

Referenties

GERELATEERDE DOCUMENTEN

In chapter 4, we describe a study in which we extensively analysed one ccRCC case using samples from multiple regions of the primary tumour, a sample from a tumour thrombus

For the detection of variants in specific genes, including known ccRCC cancer driver genes or even specific variants (i.e. hotspot analysis), targeted sequencing is more suitable

Genomic heterogeneity of clear cell renal cell carcinoma Ferronika,

Epithelial ovarian cancer (EOC) forms the vast majority of ovarian cancer cases and is now recognized as a heterogeneous disease divided into the histological

Figure 1 | SWI/SNF complex members. Other core members are shown in turquoise and exchangeable components in yellow.. Moreover, Chandler et al. demonstrated that ovarian tumor

Using the largest OCCC cell line panel established to date, we show here that BRD2 inhibition is predominantly lethal in ARID1A mutated ovarian clear cell cancer cells..

Given the large variation in mutations in VSHFL¿F JHQHV RI WKH 3,.$.7P725 and MAPK pathway between patients and the high variation in sensitivity towards PI3K and

The unresponsiveness of advanced stage ovarian clear cell carcinoma (OCCC) to platinum-based chemotherapy urges development of alternative treatment strategies.. This